{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104014","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.115241+00:00","generated_at":"2026-05-17T19:50:03.839130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%","bullets":["Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.","Adjusted EBITDA $15.2M (margin 31.1%), up 19.1% YoY; benefit from Q3 shift of annual marketing event and 503B vertical integration.","CEO announced organizational restructuring in early May to accelerate new provider and clinic growth; new leadership and upgraded sales compensation.","Q2 revenue decreased slightly YoY, but profitability and margins expanded significantly."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104014","json":"https://secwatch.observer/filing/0000950170-25-104014.json","markdown":"https://secwatch.observer/filing/0000950170-25-104014.md","text":"https://secwatch.observer/filing/0000950170-25-104014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/0000950170-25-104014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/btmd-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:50:03.839130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}